Clear Search

Showing 6 results for “race”.

April 2024
February 2024

Evaluation of RNase Therapy in Systemic Lupus Erythematosus: A Randomised Phase 2a Clinical Trial of RSLV-132

Lupus Sci Med. 2024;11:e001113 DOI 10.1136/lupus-2023-001113

Treatment with RSLV-132 was associated with lower rates of SAEs than placebo, although RSLV-132 therapy was not associated with a significant improvement in the mean CLASI score relative to placebo. However, results suggest that further evaluations of RSLV-132 in SLE should be undertaken with patients with more active disease who are most likely to benefit from RNase therapy.

more…

January 2024

Telitacicept in Patients with Active Systemic Lupus Erythematosus: Results of A Phase 2b, Randomised, Double-blind, Placebo-controlled Trial

Ann Rheum Dis. 2023; DOI: 10.1136/ard-2023-224854

This Phase 2 trial demonstrated the efficacy and acceptable safety profile of telitacicept in patients with SLE. The safety profile of telitacicept was comparable with that observed in clinical trials of other B cell-targeting agents.

more…

December 2022
May 2022

Race, Ethnicity, and Disparities in Risk of End-organ Lupus Manifestations Following SLE Diagnosis in a Multiethnic Cohort

Arthritis Care Res (Hoboken). 2022 Epub ahead of print doi: 10.1002/acr.24892

California Lupus Epidemiology Study (CLUES) finds heightened risks of developing renal, haematologic, and multiorgan disease following SLE diagnosis among Hispanic and Asian patients with SLE.

more…

Major Determinants of Prolonged Remission in Systemic Lupus Erythematosus: Retrospective Study Over a 41+ Year Period

Rheumatology (Oxford). 2022 Epub ahead of print

Retrospective observational study over a 41-year period finds complete remission (CR) in SLE to be associated with Caucasian race, older age at diagnosis, absence of renal involvement and absence of antiphospholipid syndrome.

more…